ArticleTranslational pediatrics2025
The characteristics of pulmonary fibrosis in a neonatal rat model of chronic hyperoxia lung injury.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchopulmonary dysplasia (BPD) is a common respiratory complication in premature infants, in which pulmonary fibrosis will continue to lead to the long-term impairment of pulmonary function in children with BPD and seriously affect the quality of life. This study hopes to explore the changing trend of pulmonary fibrosis characteristics of chronic hyperoxia lung injury. Methods: Newborn rats were randomly assigned to a room air (RA) group or a hyperoxia (HO) group and sampled at postnatal days (P) 3, 7, 14, 21, 28, and 42. Lung morphology was assessed using histological staining to evaluate alveolar development, collagen volume fraction (CVF), and myofibroblast distribution. Western blotting was used to measure protein expression levels of surfactant protein C (SPC), podoplanin (PDPN), cluster of differentiation 31 (CD31), and α-smooth muscle actin (α-SMA). Expression levels of fibrosis-related markers [α-SMA, Collagen I (Col I)] were evaluated at both protein and messenger ribonucleic acid (mRNA) levels using Western blot and quantitative real-time polymerase chain reaction (RT-qPCR), respectively. Additional RT-qPCR analysis was performed for fibronectin and connective tissue growth factor (CTGF). Results: At P14, HO rats exhibited decreased radical alveolar count (RAC), increased mean linear intercept (MLI), and elevated CVF compared to RA rats. SPC, CD31, and PDPN protein levels were reduced, while α-SMA increased. Collagen deposition progressively increased, peaking at P42. Col I expression rose significantly at P21 and P42. Fibronectin mRNA peaked at P21, while CTGF mRNA increased from P7 and remained elevated through P21. Conclusions: Pulmonary fibrosis in chronic hyperoxia-induced lung injury emerged by P14, peaked around P21, and stabilized thereafter. These findings offer insight into the temporal dynamics of fibrosis development in BPD and may help guide timing for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.